Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents

• Main Authors: Timo Vesikari (Author), Jerzy Brzostek (Author), Anitta Ahonen (Author), Marita Paassilta (Author), Ewa Majda-Stanislawska (Author), Leszek Szenborn (Author), Miia Virta (Author), Robert Clifford (Author), Teresa Jackowska (Author), Murray Kimmel (Author), Ilaria Bindi (Author), Pavitra Keshavan (Author), Paola Pedotti (Author), Daniela Toneatto (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The meningococcal serogroup B (MenB) protein vaccine, 4CMenB, combined with MenA, MenC, MenW and MenY polysaccharide-protein conjugates for a pentavalent MenABCWY vaccine, can potentially protect against most causative agents of invasive meningococcal disease worldwide. Two phase 2b, randomized, mul...